Precipio (NASDAQ:PRPO) Stock Rating Upgraded by Wall Street Zen

Precipio (NASDAQ:PRPO) was upgraded by stock analysts at Wall Street Zen to a “buy” rating in a research note issued on Friday.

Precipio Stock Performance

Shares of PRPO opened at $17.42 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.93 and a quick ratio of 0.69. The stock has a 50-day moving average of $15.89 and a 200-day moving average of $11.28. The company has a market cap of $28.22 million, a PE ratio of -14.64 and a beta of 1.09. Precipio has a one year low of $3.90 and a one year high of $22.38.

Precipio (NASDAQ:PRPO) last issued its earnings results on Wednesday, August 13th. The biotechnology company reported $0.05 EPS for the quarter. The company had revenue of $5.65 million during the quarter. Precipio had a negative return on equity of 15.00% and a negative net margin of 8.48%.

Institutional Trading of Precipio

An institutional investor recently bought a new position in Precipio stock. AMH Equity Ltd bought a new stake in Precipio, Inc. (NASDAQ:PRPO) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 38,294 shares of the biotechnology company’s stock, valued at approximately $240,000. AMH Equity Ltd owned approximately 2.55% of Precipio as of its most recent SEC filing. Institutional investors own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.